MDM2 Amplification Status in a Cohort of Well-Characterized Myxofibrosarcoma: A Clinicopathologic Analysis of 22 Tumors
- 27 July 2023
- journal article
- research article
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 32 (3) , 478-485
Abstract
Myxofibrosarcomas (MFS) present as slowly enlarging superficial masses in elderly patients. Even though these tumors fail to exhibit a distinct immunophenotype, diagnosis is straightforward when they present in subcutaneous tissue. Intramuscular MFS, however, are more challenging to diagnose as the differential also includes dedifferentiated liposarcoma with myxoid features. The vast majority of dedifferentiated liposarcomas show MDM2 amplification, whereas limited data exists as to the MDM2 status of MFS. We sought to explore the rate of MDM2 amplification in cases of classic MFS. Our archives were searched for MFS; only subcutaneous well-sampled resections were included. FISH for MDM2 amplification was performed on each tumor. A cohort of myxoid dedifferentiated liposarcoma resections was studied for comparison. Twenty-two MFS arose in patients aged 44 to 85 years. All tumors contained an infiltrative population of atypical cells embedded in a myxoid stroma with curvilinear blood vessels. MDM2 amplification by FISH was identified in 3 (of 22; 14%) tumors. Available follow up on 17 patients (range 1-96 months; median 13 months) revealed 6 patients with local recurrence and 1 with distant metastasis. Of 3 patients with MDM2- amplified MFS, 1 experienced recurrence and died of unrelated causes, while the second was alive without disease 12 months after diagnosis. Even though the rate of MDM2 amplification by FISH in MFS appears to be low, a subset of cases may show this genetic alteration, which pathologists should be aware of to avoid misclassification as myxoid dedifferentiated liposarcomas. Further studies are necessary to determine if amplification status adds prognostic value.Keywords
This publication has 31 references indexed in Scilit:
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism studyThe Lancet Oncology, 2012
- Advances in sarcoma genomics and new therapeutic targetsNature Reviews Cancer, 2011
- MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the boneLaboratory Investigation, 2011
- New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomicsThe Journal of Pathology, 2010
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapyNature Genetics, 2010
- Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasmsLaboratory Investigation, 2008
- Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin‐3AInternational Journal of Cancer, 2007
- Mechanisms of sarcoma developmentNature Reviews Cancer, 2003
- Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosisVirchows Archiv, 2001
- Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomasOncogene, 1999